Pharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR) announced on Tuesday that it has filed an amendment to its Mino-Lok phase 3 protocol to allow for more efficient follow-up and record-keeping of required clinical trial documentation given COVID-19 restrictions.
Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge.
Following the restrictions of personal visits, the company has issued instructions in the form of file notes to sites in April and has now formalized these instructions. The FDA released guidance on conduct of clinical trials of medical products during COVID-19 in March 2020.
In these challenging times, the company is working closely with its Principle Investigators (PIs) to keep the enormous amount of record-keeping associated with any clinical trial as simple and accurate as possible. It plans to conduct its Drug Monitoring Committee meeting as planned at the end of the month and look forward to discussions with these independent experts, stated CEO Myron Holubiak.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886